 | |
| Names | |
|---|---|
| Other names N-Methyl-4-isoleucine cyclosporin | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| ChEMBL | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
SMILES
| |
| Properties | |
| Chemical formula | C62H111N11O12 |
| Molar mass | 1202.635 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
 N verify (what is ?)
Infobox references
| |
NIM811 is a mitochondrial permeability transition inhibitor. Also known as N-methyl-4-isoleucine cyclosporin, it is a substituted cyclosporine analog that binds to cyclophilin; however, this binary complex cannot bind to calcineurin, and therefore lacks immunosuppressive activity.
NIM811 is a form of treatment for patients with the hepatitis C virus (HCV). Studies indicate a strong relationship between a treatment's cyclophilin binding affinity and suppression of HCV activity. NIM811 is also being studied as a potential treatment to genetic muscular diseases such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) disease, diseases altering the genes for collagen VI production.
References
- Ma, Sue; Boerner, Joanna E.; TiongYip, ChoiLai; Weidmann, Beat; Ryder, Neil S.; Cooreman, Michael P.; Lin, Kai (2006–2009). "NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon". Antimicrobial Agents and Chemotherapy. 50 (9): 2976–2982. doi:10.1128/AAC.00310-06. ISSN 0066-4804. PMC 1563518. PMID 16940091.
- Bernardi, Paolo; Argenton, Francesco; Bonaldo, Paolo; Braghetta, Paola; Sabatelli, Patrizia; Maraldi, Nadir Mario; Merlini, Luciano; Blaauw, Bert; Tagliavini, Francesca (2014-10-15). "NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models". Human Molecular Genetics. 23 (20): 5353–5363. doi:10.1093/hmg/ddu254. ISSN 0964-6906. PMID 24852368.